Congenital aortic valve stenosis: from pathophysiology to molecular genetics and the need for novel therapeutics

Area of Science:

• Cardiology
• Pediatric Cardiology
• Developmental Biology

Background:

• Congenital aortic valve stenosis (AVS) is a frequent cardiac malformation, affecting 3%-6% of patients.
• Congenital AVS is often progressive, necessitating lifelong interventions in both children and adults.
• The pathophysiology of congenital AVS in children differs from adult degenerative aortic valve disease, with unknown etiologies and mechanisms.

Purpose of the Study:

• To review the pathophysiology and natural history of congenitally stenotic aortic valves.
• To summarize current management strategies for congenital AVS.
• To explore genetic contributors and potential novel therapeutics for congenital AVS.

Main Methods:

• Literature review of pathophysiology, natural history, and management.
• Summary of genetic basis and identified animal models.
• Discussion of emerging therapeutic avenues.

Main Results:

• Congenital AVS requires ongoing management due to its progressive nature.
• Genetic factors are increasingly understood for congenital heart defects, but specific causes of congenital AVS remain elusive.
• Advances in molecular understanding facilitate the development of new animal models and potential therapies.

Conclusions:

• Further research is crucial to elucidate the unknown etiology and mechanisms of congenital AVS in pediatric populations.
• Integrating genetic and molecular advances holds promise for developing novel therapeutics.
• Understanding congenital AVS pathophysiology is key to improving long-term patient outcomes.